Drug Profile
AD 153
Alternative Names: AD153Latest Information Update: 14 Jul 2020
Price :
$50
*
At a glance
- Originator Apnimed
- Developer Apnimed; The Turner Institute for Brain and Mental Health
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Sleep apnoea syndrome
Most Recent Events
- 15 May 2020 Efficacy data from a phase I/II trial in Sleep apnoea syndrome presented at the 116th International Conference of the American Thoracic Society (ATS-2020)
- 17 Jul 2019 Apnimed completes a phase I/II trial in Sleep apnoea syndrome (Combination therapy) in Australia (PO) (ACTRN12618001499279)